Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$1.95
+10.2%
$1.23
$0.40
$1.97
$33.12M0.19307,572 shs481,924 shs
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
$2.97
-2.0%
$2.96
$2.67
$5.76
$26.28M1.236,430 shs36,604 shs
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$0.00
$1.50
$19.37
$7.07M2.899,592 shs4,300 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$0.71
+1.1%
$0.50
$0.24
$4.47
$23.50M0.65956,708 shs253,298 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.00%+14.94%+19.59%+172.06%+106.05%
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
0.00%-5.31%+4.84%+5.21%-43.86%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
0.00%-16.13%+51.89%+137.60%-76.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.5832 of 5 stars
0.03.00.00.03.30.80.0
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
1.3804 of 5 stars
3.33.00.00.01.50.00.0
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
4.808 of 5 stars
3.15.00.04.43.34.21.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.00
N/AN/AN/A
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
2.50
Moderate Buy$12.00304.04% Upside
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
0.00
N/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.25
Hold$5.00606.11% Upside

Current Analyst Ratings Breakdown

Latest INNVD, DARE, ABVC, and RLMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2025
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$508.38K65.14N/AN/A$1.02 per share1.91
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
$25.91K1,014.49N/AN/A($0.61) per share-4.87
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
$23.99M0.00N/AN/A$0.05 per share0.00
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$2.84 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-$10.52M-$0.13N/AN/A-1,619.65%-104.94%-56.81%8/12/2025 (Estimated)
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
-$30.16M-$0.17N/AN/AN/A-191.65%N/A-18.98%8/11/2025 (Estimated)
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
-$8.28M-$4.16N/A0.00N/A-34.51%-682.54%-78.57%N/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$98.79M-$2.51N/AN/AN/AN/A-129.80%-112.06%8/6/2025 (Estimated)

Latest INNVD, DARE, ABVC, and RLMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million
5/12/2025Q1 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.31-$0.58-$0.27-$0.58N/AN/A
4/30/2025Q4 2024
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A-$0.06N/A-$0.06N/AN/A
4/15/2025Q4 2024
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A$0.04N/A$0.04N/AN/A
3/31/2025Q4 2024
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
-$0.66-$0.64+$0.02-$0.64$1.00 million($0.06) million
3/27/2025Q4 2024
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.70-$0.62+$0.08-$0.62N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/AN/AN/AN/AN/A
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
N/AN/AN/AN/AN/A
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A
0.34
0.34
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
N/A
1.14
1.14
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
N/A
0.68
0.36
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
6.89
6.89

Institutional Ownership

CompanyInstitutional Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
11.38%
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
6.70%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
10.38%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%

Insider Ownership

CompanyInsider Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
17.10%
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
4.00%
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
16.43%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
20.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
3016.98 million11.43 millionNot Optionable
Daré Bioscience, Inc. stock logo
DARE
Daré Bioscience
308.85 million8.35 millionNot Optionable
Innovus Pharmaceuticals Inc stock logo
INNVD
Innovus Pharmaceuticals
122.36 millionN/ANot Optionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million24.74 millionOptionable

Recent News About These Companies

Relmada Therapeutics to hold a virtual meeting
Relmada Therapeutics To Present NDV-01 Data at AUA2025
Q4 2024 Relmada Therapeutics Inc Earnings Call
Relmada Therapeutics reports Q4 EPS (62c) vs. (84c) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC BioPharma stock logo

ABVC BioPharma NASDAQ:ABVC

$1.95 +0.18 (+10.17%)
Closing price 04:00 PM Eastern
Extended Trading
$1.89 -0.06 (-3.03%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Daré Bioscience stock logo

Daré Bioscience NASDAQ:DARE

$2.97 -0.06 (-1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$2.98 +0.01 (+0.51%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Innovus Pharmaceuticals stock logo

Innovus Pharmaceuticals OTCMKTS:INNVD

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$0.72 +0.02 (+2.40%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.